Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) EBT Margin (2020 - 2025)

Vivos Therapeutics' EBT Margin history spans 6 years, with the latest figure at 181.85% for Q4 2025.

  • Quarterly results put EBT Margin at 181.85% for Q4 2025, down 10540.0% from a year ago — trailing twelve months through Dec 2025 was 121.72% (down 4763.0% YoY), and the annual figure for FY2025 was 121.71%, down 4762.0%.
  • EBT Margin for Q4 2025 was 181.85% at Vivos Therapeutics, down from 79.61% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 452.05% in Q4 2022 to a low of 181.85% in Q4 2025.
  • The 5-year median for EBT Margin is 104.32% (2021), against an average of 61.4%.
  • The sharpest move saw EBT Margin surged 48336bps in 2021, then plummeted -58318bps in 2023.
  • Year by year, EBT Margin stood at 293.9% in 2021, then surged by 54bps to 452.05% in 2022, then crashed by -129bps to 131.13% in 2023, then surged by 42bps to 76.45% in 2024, then plummeted by -138bps to 181.85% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 181.85%, 79.61%, and 131.23% for Q4 2025, Q3 2025, and Q2 2025 respectively.